Actively Recruiting
Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke
Led by Central Hospital, Nancy, France · Updated on 2025-06-05
626
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days. Achieving the best possible angiographic reperfusion is a key determinant of clinical outcome in acute ischemic stroke patients with anterior circulation large vessel occlusion. Mechanical thrombectomy is standard treatment for large vessel occlusion stroke patients within 24. In the setting of successful (eTICI ≥2b), adjunct intra-arterial thrombolysis may be a promising therapeutic option allowing recanalization of distal arterial occlusions (not accessible to mechanical devices) and improvement of upstream brain reperfusion by targeting microvascular obstruction. The IA-SUCCESS randomized trial aims to assess the clinical and safety of adjunct intra-arterial thrombolysis vs. no adjunct intra-arterial thrombolysis after successful angiographic reperfusion in patients with acute anterior circulation large vessel occlusion stroke.
CONDITIONS
Official Title
Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pre-stroke modified Rankin Scale (mRS) score between 0 and 2
- Acute ischemic stroke with anterior circulation large vessel occlusion (intracranial internal carotid artery, M1, or M2) confirmed by CT or MRI
- NIHSS score of 5 or more at admission
- Acute reperfusion treatment started within 24 hours of stroke onset according to guidelines
- DWI-ASPECTS of 2 or higher (MRI) or CT-ASPECTS of 3 or higher
- Imaging to puncture time within 3 hours for transferred patients
- Successful angiographic reperfusion (eTICI 2b-3) after intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy confirmed by catheter angiogram
- Affiliation to or beneficiary of a social security plan
You will not qualify if you...
- Inability to speak French
- Contraindications to intra-arterial thrombolysis such as platelet count below 100,000/mm3, INR above 1.7, recent oral anticoagulant use within 48 hours or confirmed activity, or effective heparin treatment
- Bleeding risk complications during mechanical thrombectomy (e.g., carotid dissection, complicated femoral approach)
- Bleeding risk complications related to fall associated with stroke
- Use of more than 5 thrombectomy devices
- Presence of intracerebral hemorrhage
- Occlusion or severe stenosis treated by stenting
- Expected inability to attend 3-month follow-up visit
- Participation in another clinical trial within 30 days prior that may affect 90-day outcome
- Woman of childbearing age without effective contraception
- Persons excluded by French Public Health Code articles L.1121-5, L.1121-7, and L.1121-8
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU Nancy
Nancy, France, 54000
Actively Recruiting
Research Team
B
Benjamin GORY, MD, PHD
CONTACT
G
Guillaume TURC, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here